Reasons to buy the ‘State of the Biopharmaceutical Industry 2025’ strategic intelligence report:

Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, including:

Emerging technologies

Regulatory trends

Macroeconomic trends

Industry trends

Predict the industry’s growth prospects in the next 12 months.

Examine the policies and regulations including the key industry events such as EU Pharma Reform, BIOSECURE Act, Inflation Reduction Act, etc.

Get an insight into other critical topics including biotech funding, an early preview of the clinical trial landscape in 2025, and key anticipated drug launches.

How is our ‘State of the Biopharmaceutical Industry 2025’ report unique from other reports in the market?

Understand the business environment and the industry, regulatory, and macroeconomic trends shaping the biopharmaceutical industry in the next 12 months.

Analyse the impact of major themes on the biopharmaceutical industry in the next 12 months.

Identify themes that will have the greatest positive or negative impact in the coming months.

Comprehend the opinions of industry respondents on these themes.

We recommend this valuable source of information to anyone involved in:

​​​​Drug Development and ​​​​Pharma/Biotech Companies – Value chain

Pharmaceutical Industry Suppliers and Distributors

Pharma/Drug Manufacturing Companies – Leaders and Startups

Business Development and Market Intelligence

Investment Analysts and Portfolio Managers

Professional Services – Investment Banks, PE/VC Firms

M&A/Investment, Management Consultants, and Consulting Firms

State of the Biopharmaceutical Industry 2025 – Strategic Report Overview

The biopharmaceutical industry is optimistic about its growth prospects in 2025, but the levels of optimism are lower than six months ago. The reduced optimism may stem from factors like the potential impact of the US BIOSECURE Act, cautiousness about the strong recovery of biotech funding, and challenges associated with changes in government. Furthermore, continuous escalations in geopolitical tensions, including ongoing conflicts, are adding uncertainty, potentially contributing to a more wary outlook for the industry.

The “State of the Biopharmaceutical Industry 2025” strategic intelligence report examines the business environment, challenges, and the latest biopharma market trends. The biopharma innovation report highlights the most impactful emerging technologies, industry trends, regulatory trends, and macroeconomic factors that are going to impact and biotech industry growth throughout the next 12 months.

Biopharmaceutical Industry - Emerging Trends

Pharmaceutical industry professionals rated immuno-oncology drug development, anti-obesity medications, complexity and increasing costs of clinical trials, real-world evidence (RWE), cell and gene therapy (CGTs), personalized/ precision medicine, and others as the most impactful emerging industry trends. Immuno-oncology (IO) drug development was identified as the top emerging pharmaceutical industry trend for 2024.

CGTs, personalized/precision medicine, and IO drug development are closely related trends that have already begun to reshape disease treatment paradigms and the provision of healthcare. Their influence will continue to grow as additional drugs reach the market. Furthermore, the emphasis on tailored disease prevention and treatment will continue to be the driver and enabler for value-based healthcare.

Emerging Technologies in the Biopharmaceutical Industry

The most disruptive emerging technologies that will influence the biopharmaceutical industry are AI, big data, data integration/data lakes, cybersecurity, and social media among others. AI and big data are poised to significantly optimize the entire pharmaceutical value chain with their combines capabilities. This powerful duo has the potential to enhance a wide variety of processes, ranging from target identification to end-user reach.

AI and big data in healthcare are linked. Data derived from numerous pharmaceutical processes can only add value if it is properly analyzed and produces actionable results. As a data-driven algorithm, AI requires high-quality data. The more data AI receives, the more accurate and efficient it can become. Furthermore, AI’s appeal to the pharmaceutical industry lies in its ability to accelerate processes like drug discovery, reduction of R&D costs, and prediction of patient outcomes with unprecedented precision.

Therapy Areas in the Biopharmaceutical Industry

The top therapy areas in the biopharmaceutical industry are oncology, metabolic disorders, immunology, infectious disease, and central nervous system, among others. Oncology remains the single largest therapy area going into 2025, driven by leading drugs such as Keytruda, Darzalex/Faspro, and Opdivo.

Biopharmaceutical Industry – Competitive Landscape

Top industry sponsors for planned clinical trials in 2025 include Bio-Innova, Novartis, Pfizer, Takeda Pharmaceutical, and AstraZeneca, among others. In 2025, Bio-Innova accounts for the most phase 1 clinical trials in 2025.